Gilead has gotten a new HIV preventive treatment, Yeztugo, approved, which consists of two injections a year, promising more effective prevention.
Lara Maior
Current Affairs
Foto Gilead Pharma
Always see our news on Google
Yeztugo, a drug developed by Gilead, has been authorized in the United States as a preventive treatment against HIV. It requires only two injections a year, unlike current treatments that require daily pills. While the treatment could revolutionize the fight against the AIDS epidemic, cost remains a crucial issue, with an estimated annual price tag of about $25,000. UNAIDS director Winnie Byanyima emphasized the importance of making the drug affordable to have a real impact in the fight against AIDS.
Sources
Tratament promiţător împotriva HIV-SIDA. Producătorii promit prețuri accesibil
Statele Unite autorizează un nou tratament preventiv, foarte promiţător, împotriva HIV, virusul care cauzează SIDA
FDA approves first twice-yearly injection that prevents HIV infection
US approves promising preventive HIV treatment
Groundbreaking twice-a-year HIV drug that could stop transmission approved
Latest News
14:56
Prime Minister Vasile Tofan thanked the United States for funding the Strășeni-Gutinaș power line, a 400 kV project that will strengthen the energy security of the Republic of Moldova.
14:40
OpenAI prohibits ChatGPT from imitating the literary style of famous authors
14:27
The Italian sneaker brand Golden Goose is preparing to enter the Romanian market
See more news
NEWS ON THE SAME TOPICS
.webp)
.webp)
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
